Shimomura Y, Hara M, Hirabayashi S, Kondo T, et al. Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone Marrow Transplant 2021 Jun 21. pii: 10.1038/s41409-021-01380.
PMID: 34155357